Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Xếp hạng trong cổ phiếu #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Giá cổ phiếu
$149.90
Đồng bộ lần cuối: 2026-09-18
Vốn hóa thị trường
$284.92B
Thay đổi (1 ngày)
-0.66%
Thay đổi (1 năm)
21.93%
Quốc gia
CH
Giao dịch Novartis AG (NOVN)

Danh mục

Lịch sử giá cổ phiếu của Novartis AG (NOVN)
Giá đóng cửa cao nhất: $155.10 vào 2026-09-01

Giá đóng cửa thấp nhất: $19.02 vào 1995-04-01
Lịch sử giá cổ phiếu của Novartis AG từ 1995 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 10.79%
2025 34.64%
2024 1.69%
2023 8.06%
2022 8.71%
2021 -8.14%
2020 -2.05%
2019 20.72%
2018 3.40%
2017 19.32%
2016 -17.48%
2015 -9.35%
2014 20.80%
2013 23.98%
2012 13.54%
2011 -2.30%
2010 4.11%
2009 15.79%
2008 -14.72%
2007 -4.76%
2006 10.95%
2005 6.32%
2004 13.45%
2003 19.37%
2002 4.81%
2001 -12.71%
2000 12.71%
1999 -56.75%
1998 15.24%
1997 58.59%
1996 48.26%
1995 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
$1.15K 53.22%
US
$269.75 53.10%
US
$263.75 18.56%
US
$474.96 36.76%
CH
$146.40 79.61%
US